glp 1 vs glp 1 ra Exploring GLP-1 Receptor Agonists (GLP-1 RAs): R&D Advances and Tackling Bioanalytical Challenges Comparison of short-acting versus long-acting

Others prefer injections for convenience and more controlled exposure

Huge thanks to my university press office and supportive colleagues for facilitating this important conversation, and to Dr Martin Whyte for his distinctive contributions and insights

For those who fear injections, and might be waiting for the pill-form to actually try Ozempic, rejoice, as it is predicted to be launched some time in 2025 or 2026, and when that eventually happens, we will see a dramatic swell of those taking the medication for weight loss

Historically, the obesity pharmacotherapy literature notes early trial signals and also that development was terminated after failure to show meaningful weight loss in a larger, longer trial (as summarized in a peer-reviewed review discussing a 12-week signal and a later 24-week negative result)

doi: 10.3389/fimmu.2017.01875 50 KushnerIRzewnickiDL